
## **Charles James**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3457931/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Neural stem cells secreting bispecific T cell engager to induce selective antiglioma activity. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	18
2	A first-in-human phase 0 clinical study of RNA interference–based spherical nucleic acids in patients with recurrent glioblastoma. Science Translational Medicine, 2021, 13, .	12.4	136
3	EXTH-18. PEPTIDE NANO-STRUCTURES ENHANCE PEDIATRIC BRAIN TUMOR CHEMOTHERAPEUTIC EFFICACY. Neuro-Oncology, 2019, 21, vi86-vi86.	1.2	0
4	TMOD-20. COMBINING TARGETED INHIBITOR AND RADIOTHERAPY IN TREATING ANAPLASTIC MENINGIOMA. Neuro-Oncology, 2019, 21, vi266-vi267.	1.2	0
5	EPEN-30. HISTONE H3 LYSINE 4 TRIMETHYLATION IS A POTENTIAL TARGET TO IMPROVE CHEMOTHERAPEUTIC EFFICACY FOR PEDIATRIC PRIMARY EPENDYMOMAS. Neuro-Oncology, 2018, 20, i79-i79.	1.2	0
6	Detection of histone H3 K27M mutation and post-translational modifications in pediatric diffuse midline glioma via tissue immunohistochemistry informs diagnosis and clinical outcomes. Oncotarget, 2018, 9, 37112-37124.	1.8	44
7	Therapeutic Hypothesis Testing With Rodent Brain Tumor Models. Neurotherapeutics, 2017, 14, 385-392.	4.4	8
8	miR-182 integrates apoptosis, growth, and differentiation programs in glioblastoma. Genes and Development, 2015, 29, 732-745.	5.9	182
9	Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nature Medicine, 2014, 20, 1394-1396.	30.7	411
10	Targeted Therapy for <i>BRAFV600E</i> Malignant Astrocytoma. Clinical Cancer Research, 2011, 17, 7595-7604.	7.0	143
11	Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell, 2010, 17, 98-110.	16.8	6,138
12	Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts. Neuro-Oncology, 2009, 11, 477-487.	1.2	115
13	Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy. Journal of Neurosurgery, 2007, 107, 610-616.	1.6	74
14	Use of an Orthotopic Xenograft Model for Assessing the Effect of Epidermal Growth Factor Receptor Amplification on Glioblastoma Radiation Response. Clinical Cancer Research, 2006, 12, 2264-2271.	7.0	242
15	Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro-Oncology, 2005, 7, 164-176.	1.2	296